Indoco Remedies announced that the Board of Directors of the Company at its meeting held on 16 May 2024, has recommended a Final dividend of Rs.1.50 per share (i.e.75%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Indoco Remedies declined 12.05% to Rs 22.70 crore in the quarter ended March 2024 as against Rs 25.81 crore during the previous quarter ended March 2023. Sales rose 2.41% to Rs 439.08 crore in the quarter ended March 2024 as against Rs 428.75 crore during the previous quarter ended March 2023.For the full year,net profit declined 30.78% to Rs 98.47 crore in the year ended March 2024 as against Rs 142.25 crore during the previous year ended March 2023. Sales rose 9.03% to Rs 1788.22 crore in the year ended March 2024 as against Rs 1640.05 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales439.08428.75 2 1788.221640.05 9 OPM %11.1315.10 -13.6617.44 - PBDT39.4856.62 -30 216.14263.41 -18 PBT13.2538.93 -66 124.27192.80 -36 NP22.7025.81 -12 98.47142.25 -31 Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 16 May 2024Powered by Capital Market - Live News

Indoco Remedies has allotted 31,850 equity shares under ESOP on 29 March 2024. Consequent to this allotment, the paid-up capital of the Company stands increased from Rs. 18,43,00,710 (consisting of 9,21,50,355 equity shares of face value of Rs. 2 each) to Rs. 18,43,64,410 (consisting of 9,21,82,205 equity shares of face value of Rs. 2 each).Powered by Capital Market - Live News

Indoco Remedies announced that its wholly owned subsidiary, Warren Remedies has commenced its commercial production on 24 March 2024 from its greenfield manufacturing facility located at Aurangabad, Maharashtra to manufacture Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs).Powered by Capital Market - Live News